Research-use-only context. This article summarizes published third-party scientific literature and laboratory practice. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. US Prime Peptides products are supplied strictly for in vitro laboratory research and are not for human or veterinary use.
"503A," "503B," and "research use only" are three labels that get attached to peptides, and they describe three different legal situations rather than three grades of the same thing. This article explains what each category is, who operates under it, what each can and cannot supply, and why a research vial is not a compounded preparation under either section of the statute. It is a regulatory explainer, not legal advice.
The short answer: three categories, one molecule, three different rules
Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) covers compounding by a licensed pharmacist or physician for a named individual under a prescription. Section 503B covers registered "outsourcing facilities" that compound under FDA oversight and may supply office stock without a prescription. "Research use only" (RUO) is not a section of the statute at all; it describes a chemical sold and labeled as a laboratory reagent whose intended use is in vitro work. The same amino-acid sequence can exist in all three worlds, but the paperwork, the oversight, and the lawful destination of the product are different in each.
Both compounding sections are exemptions from the new-drug approval requirement and from the labeling rule that requires adequate directions for use. The FDA's own question-and-answer page is blunt about what that means: compounded drugs are not approved by the FDA, and the agency does not verify their safety, effectiveness, or quality before they are marketed. An RUO reagent is not a drug at all when it is sold for laboratory use; it becomes an unapproved drug the moment anyone in the chain intends it for use in a person or an animal. The intended-use framework is covered in a separate article.
Section 503A: pharmacy compounding for a named individual
Section 503A (codified at 21 U.S.C. 353a) exempts a compounded drug from approval, from the adequate-directions labeling rule, and from current good manufacturing practice (CGMP) when a licensed pharmacist in a state-licensed pharmacy or Federal facility, or a licensed physician, compounds it for a specific identified person on the basis of a valid prescription from a practitioner authorized by state law to prescribe. The statute allows limited compounding in anticipation of a prescription, but only on the strength of a history of valid orders within an established relationship. Day-to-day oversight of 503A compounders sits with state boards of pharmacy; the FDA conducts surveillance and for-cause inspections.
The ingredient rules are the part that matters most for peptides. Under 353a(b)(1)(A), a bulk substance used in 503A compounding must satisfy one of three paths: it complies with an applicable United States Pharmacopeia or National Formulary monograph; or, if no monograph exists, it is a component of a drug approved by the FDA; or, failing both, it appears on the 503A bulks list the agency develops under subsection (c). Every bulk substance must also be made by an establishment registered with the FDA and arrive with a valid certificate of analysis. The FDA's interim policy sorts nominated substances into three categories: Category 1 (may be eligible, sufficient information, no enforcement intended while evaluation continues), Category 2 (sufficient information but the FDA "has identified significant safety risks"), and Category 3 (nominated with "insufficient supporting information for FDA to evaluate them"). The FDA's current page on substances that may present significant safety risks lists kisspeptin-10 in Category 2 for 503A, and records a long roster of other peptides, including BPC-157, CJC-1295, AOD-9604, and thymosin alpha-1, under the heading of substances that were nominated but withdrawn.
Section 503B: outsourcing facilities under federal oversight
Section 503B (21 U.S.C. 353b) was created by the Drug Quality and Security Act, signed November 27, 2013, after a 2012 fungal meningitis outbreak linked to poorly made compounded drugs. An outsourcing facility is defined in the statute as "a facility at one geographic location or address that" compounds sterile drugs, has elected to register with the FDA, and complies with the section's requirements. It need not be a licensed pharmacy, and it may compound with or without prescriptions for identified individuals; that is why a 503B facility can ship office stock to a practice in response to a clinician's order that is not tied to a specific person.
The trade-off for that flexibility is federal oversight. Outsourcing facilities register annually between October 1 and December 31, pay fees, report the drugs they compounded every June and December, file adverse-event reports, and are inspected on a risk-based schedule. Unlike 503A compounders, the FDA states plainly that "outsourcing facilities are subject to CGMP requirements." Labels must state that the drug is compounded, identify the facility, and carry the lot or batch number, the compounding and expiration dates, storage information, "Not for resale," and the ingredient list.
Bulk-substance rules are tighter than under 503A. A 503B facility generally cannot compound from a bulk substance unless it is on the 503B bulks list of substances "for which there is a clinical need" or the finished drug is on the FDA's shortage list at the time of compounding, distribution, and dispensing; the substance must again come from a registered establishment with a valid certificate of analysis. The same three interim categories apply. On September 29, 2023, the FDA placed GHRP-2, GHRP-6, and ipamorelin acetate in Category 2 for 503B, citing immunogenicity concerns and reported serious adverse events. The FDA has also stated that substances nominated on or after January 7, 2025 will not be placed into the interim categories at all.
Research use only: a reagent category, not a compounding exemption
A research-use-only peptide is a chemical sold for in vitro laboratory work. It is not compounded for a named individual, it is not compounded as office stock by a registered facility, and no clinician's order is involved in its supply. Its legal footing rests on intended use: a supplier who labels, markets, and sells the material as a laboratory reagent, and who documents it as one, is selling a chemical rather than a drug. What "research use only" obligates is covered elsewhere on this site; the short version is that the label is a statement of intended use that the supplier must honor consistently, not a loophole that permits human use.
Because an RUO reagent is not a 503A or 503B product, none of the compounding machinery applies to it: no prescription, no pharmacy license for the supplier, no 503B registration, no FDA release of the lot, and no "compounded" label. What a serious research supplier provides instead is analytical documentation: a lot-matched certificate of analysis reporting identity, purity, net peptide content, endotoxin, sterility, and heavy metals, plus an independent laboratory's report. That documentation describes the chemistry of the lot; it is not a release of the material for use in people. US Prime Peptides sells under a physician-use, research-use-only model, and its certificates are posted on product pages before purchase because the buyer, not a pharmacist, is the one who will evaluate the material.
Side-by-side: who, what, and under whose oversight
The table below compares the three categories on the questions a practice manager usually asks, drawing on the FDA's compounding pages and the statute.
| Question | 503A compounding | 503B outsourcing facility | Research use only (RUO) |
|---|---|---|---|
| Statutory basis | 21 U.S.C. 353a | 21 U.S.C. 353b (added by DQSA, 2013) | None specific; intended-use provisions of the FDCA |
| Who makes it | Licensed pharmacist or physician | Registered outsourcing facility, under a licensed pharmacist | Chemical supplier or synthesis laboratory |
| Prescription required | Yes, for an identified individual (limited anticipatory compounding allowed) | Optional; may supply office stock on a practitioner's order | No; not a drug when sold for in vitro research |
| Primary oversight | State board of pharmacy; FDA surveillance | FDA registration, fees, reporting, risk-based inspection | General FDCA intended-use and labeling rules; FTC advertising rules |
| CGMP applies | Exempt | Yes | Not applicable (not a drug when sold as a reagent) |
| Bulk-substance rule | USP/NF monograph, component of an approved drug, or 503A bulks list; registered source; COA | 503B bulks list (clinical need) or shortage list; registered source; COA | Supplier's own lot-matched COA and independent testing |
| Intended destination | A specific person under a prescriber's care | A practice's stock or a specific person | A laboratory bench; in vitro work only |
| Product label says | Compounded preparation, prescription label | "This is a compounded drug," facility name, lot, dates, "Not for resale" | "For research use only. Not for human or veterinary use." |
Why a research vial is not a compounded product, and a compounded product is not a research vial
The two categories do not overlap, and a supplier that blurs them creates risk for everyone downstream. A research vial has no prescription behind it, carries no "compounded" statement, was not prepared under either exemption, and is not offered as a bulk ingredient for compounding. Its certificate is an analytical report on a specific lot, not a pharmacy's release. Conversely, a compounded preparation from a 503A pharmacy or a 503B facility is a drug prepared for human use under a legal exemption; it is not a laboratory reagent.
The peer-reviewed literature reinforces the point. A 2018 review in the Journal of Drugs in Dermatology walked through the 503A and 503B framework and the obligations each imposes on prescribers. A 2021 American Journal of Health-System Pharmacy paper described a pharmacist-run FDA program for surveilling quality incidents involving compounded drugs, oversight that exists for the compounding categories and not for anything sold as a reagent. A 2023 International Journal of Pharmaceutical Compounding article describes what a compounder must verify about a bulk-substance source. And a 2024 Journal of Medical Internet Research surveillance study of NN9535 sold online without a prescription found quality and labeling problems across sellers, which is why a practice should ask which category it is buying under before anything arrives. A research supplier's answer should be unambiguous: RUO, documented as such, with the regulatory status of each compound stated plainly.
Frequently Asked Questions
What is the difference between 503A and 503B peptides?
A 503A preparation is compounded by a licensed pharmacist or physician for a specific identified person under a prescription, with day-to-day oversight by a state board of pharmacy and no CGMP requirement. A 503B preparation comes from a registered outsourcing facility that must follow CGMP, pay fees, report to the FDA twice a year, and may supply office stock without a prescription. Neither is approved by the FDA; both are exemptions from the approval requirement.
Is a research-use-only peptide the same as a compounded peptide?
No. A research-use-only peptide is a chemical sold for in vitro laboratory work; no prescription, pharmacy license, outsourcing-facility registration, or FDA release is involved, and it is not labeled as a compounded drug. A compounded peptide is a drug prepared for human use under section 503A or 503B. The two are different legal categories even when the amino-acid sequence is identical.
Can a 503A pharmacy compound with any peptide?
No. A 503A bulk substance must comply with a USP or NF monograph, be a component of a drug approved by the FDA, or appear on the 503A bulks list, and it must come from a registered manufacturer with a valid certificate of analysis. Many peptides nominated for the list were withdrawn or placed in categories that do not carry the FDA's non-enforcement policy, and the agency has said substances nominated on or after January 7, 2025 will not be placed in the interim categories.
Does a 503B outsourcing facility need a prescription?
Not necessarily. The statute says an outsourcing facility may or may not obtain prescriptions for identified individuals, which is why it can ship office stock to a practice on a practitioner's order. In exchange, it must register with the FDA, follow CGMP, report compounded products and adverse events, and submit to risk-based inspection.
Citations
- US FDA. Human Drug Compounding Laws (sections 503A and 503B; Drug Quality and Security Act of 2013). fda.gov
- US FDA. Compounding and the FDA: Questions and Answers (content current as of September 16, 2025). fda.gov
- US FDA. Information for Outsourcing Facilities. fda.gov
- US FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of May 14, 2026). fda.gov
- US FDA. Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act (content current as of January 7, 2025). fda.gov
- US FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026). fda.gov
- 21 U.S.C. 353a, Pharmacy compounding. Legal Information Institute, Cornell Law School. law.cornell.edu
- 21 U.S.C. 353b, Outsourcing facilities. Legal Information Institute, Cornell Law School. law.cornell.edu
- Quertermous J, Desai S, Harper J, et al. The Practice of Compounding, Associated Compounding Regulations, and the Impact on Dermatologists. J Drugs Dermatol. 2018;17(7):s17-s22. PMID 30005109
- Janusziewicz AN, Glueck SN, Park SY, et al. A pharmacist-driven FDA incident surveillance and response program for compounded drugs. Am J Health Syst Pharm. 2021;78(15):1438-1443. PMID 33889929
- Summers A. Considerations in Qualifying Critical Suppliers. Int J Pharm Compd. 2023;27(6):461-466. PMID 38100663
- Ashraf AR, Mackey TK, Vida RG, et al. Multifactor Quality and Safety Analysis of NN9535 Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. J Med Internet Res. 2024;26:e65440. PMID 39509151
This article is for laboratory research reference only. US Prime Peptides products are supplied strictly for in vitro research. Not for human consumption.
Related research
- What 'Research Use Only' Actually Means on a Peptide Label
- Are Research Peptides Legal in the United States? What the Rules Actually Say
- Why a Second Laboratory Matters: Independent Testing vs Manufacturer Certificates
- How to Vet a Research Peptide Vendor: A 12-Point Checklist
- FDA Status of Common Research Peptides: A Reference Table
Compliance Notice: US Prime Peptides products are supplied strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution’s safety protocols and applicable laws.
